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Abstract RXRA regulates transcription as part of a heterodimer with 14 other nuclear receptors,
including the peroxisome proliferator-activated receptors (PPARs). Analysis from TCGA raised the
possibility that hyperactive PPAR signaling, either due to PPAR gamma gene amplification or RXRA
hot-spot mutation (S427F/Y) drives 20–25% of human bladder cancers. Here, we characterize
mutant RXRA, demonstrating it induces enhancer/promoter activity in the context of RXRA/PPAR
heterodimers in human bladder cancer cells. Structure-function studies indicate that the RXRA
substitution allosterically regulates the PPAR AF2 domain via an aromatic interaction with the
terminal tyrosine found in PPARs. In mouse urothelial organoids, PPAR agonism is sufficient to
drive growth-factor-independent growth in the context of concurrent tumor suppressor loss.
Similarly, mutant RXRA stimulates growth-factor-independent growth of Trp53/Kdm6a null bladder
organoids. Mutant RXRA-driven growth of urothelium is reversible by PPAR inhibition, supporting
PPARs as targetable drivers of bladder cancer.
DOI: https://doi.org/10.7554/eLife.30862.001
Introduction
Bladder cancer is the sixth most common cancer in the US and is predicted to cause ~17,000 deaths
in 2017 [The website of the National Cancer Institute (https://www.cancer.gov)]. In contrast to other
common malignancies, bladder cancer management has not yet benefited from molecularly targeted
therapies. Early phase clinical data with agents targeting FGFR3 or ERBB family members have
shown encouraging activity in the minority of patients with oncogenic versions of these kinases
(Nogova et al., 2017; Choudhury et al., 2016), but identification of new targetable genomic drivers
is needed to expand the armamentarium. Nuclear receptors are amongst the most successful thera-
peutic targets in oncology, with small molecule inhibitors of estrogen receptor (ER) and androgen
receptor (AR) improving survival in breast and prostate cancers (Fisher et al., 1996; Beer et al.,
2014). The established ability to modulate nuclear receptors with drugs makes them an attractive
class of targets for other cancer types when there is compelling evidence supporting their role as
tumor drivers.
RXRA is a nuclear receptor that regulates transcription as a homodimer or as an obligate hetero-
dimerization partner for 14 other nuclear receptors, including the three peroxisome proliferator-acti-
vated receptors PPARA, PPARD, and PPARG (Evans and Mangelsdorf, 2014). Exome analysis of
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bladder cancer samples across three independent cohorts identified mutations at RXRA S427 in 5–
8% of cases, always leading to an amino acid substitution with an aromatic amino acid, phenylalanine
(~5%) or tyrosine (~1%) (Cancer Genome Atlas Research Network, 2014; Guo et al., 2013;
Van Allen et al., 2014). Reported analysis from TCGA found evidence of up-regulated PPAR path-
way activity in RXRA hot-spot mutant cases (Cancer Genome Atlas Research Network, 2014).
Copy number analysis identified PPARG as amplified in 17% of bladder cancer cases
(Cancer Genome Atlas Research Network, 2014), with PPARG amplified cases being highly
enriched for PPARG mRNA expression (q value = 2.6  10-9) (Cerami et al., 2012). These data
raised the possibility that hyperactive PPAR signaling, either due to gene-amplification-driven hyper-
expression or RXRA hot-spot mutation may drive 20–25% of bladder cancers. Here, we characterize
structural and biological consequences of the RXRA hot-spot mutations.
Results
Mutant RXRA induces PPAR transcriptional signaling at the canonical
DR1 motif
To establish a causal role of RXRA hot-spot mutations in hyper-activation of PPAR singling, we used
retroviral transduction to introduce wild-type or mutant RXRA into two bladder cancer cell lines,
JMSU-1 and 575A. Equivalent RXRA expression levels were confirmed by qPCR and western blot
(Figure 1A). RNA-seq was used to compare transcriptomes in the wild-type and S427F RXRA
expressing cells. Gene transcripts robustly up-regulated by the mutation (twofold, FDR <0.05) were
analyzed using over-representation analysis (ORA) to identify enriched pathways. In both cell lines,
the PPAR signaling pathway (KEGG-hsa03320) was the top scoring hit. When the ORA was limited
to genes up-regulated by the mutation in both cell lines, again PPAR signaling was the top hit
(Figure 1B, Figure 1—source data 1). We also compared transcriptome changes induced by the
RXRA mutation to those induced after treating RXRAwt expressing cells with the PPARG agonist pio-
glitazone. There was robust correlation in both JMSU-1 and 575A (Pearson r = 0.72, p=1.4  10 34
or 3.1  10 105), confirming that the mutation drives expression changes similar to agonist-induced
PPAR activation (Figure 1C). Mutation-driven hyper-activation of PLIN2 and FABP3, two genes
eLife digest Bladder cancer is the sixth most common type of cancer in the United States. At
the moment, treatment options for advanced bladder cancer are limited to chemotherapy and
immunotherapy, both of which benefit only some patients. Many other types of cancer can be
treated with drugs that are specific to genetic mutations found in those cancer cells, often making
the treatments more efficient with fewer side effects.
Between 5–8% of people with bladder cancer have a mutation in the gene that produces a
protein called RXRA. This protein partners with itself or with other proteins to control gene activity.
However, it was not clear what mutant RXRA proteins do in bladder cancer cells.
Halstead et al. studied the RXRA mutation in human bladder cancer cells and “mini-bladders”
grown in the laboratory from mouse bladder cells. Biochemical experiments showed that the mutant
RXRA protein causes abnormally high activity in one group of its partner proteins, called peroxisome
proliferator-activated receptors (PPARs). The PPARs, in turn, switch on genes that help cancer cells
to grow and multiply. Computational simulations of the mutant RXRA binding to PPARs revealed, at
a molecular level, how this activation occurs. Lastly, Halstead et al. used chemicals that block the
activity of PPARs to stop the growth of cells in the mouse mini-bladders that contained the RXRA
mutation.
These findings suggest that bladder cancer patients with the RXRA mutation may benefit from
therapies that inhibit PPARs. Such therapies could also benefit the approximately 15–20% of people
with bladder cancer who do not have the RXRA mutation but who do have over-active PPARs.
Although there are chemicals that block the activity of PPARs, more research is needed to refine
them before they can be used to treat cancer.
DOI: https://doi.org/10.7554/eLife.30862.002
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Figure 1. RXRA hot-spot mutations induce the PPAR signaling pathway by activating enhancer/promoters with a canonical PPAR response element. (A)
JMSU-1 and 575A cells were transduced with pBABE retrovirus to express indicated RXRA alleles and expression confirmed by western blot (top) or RT-
qPCR in triplicate ± SD (data expressed as a fraction of actin signal). (B) Protein coding transcripts up-regulated greater than or equal to twofold
Figure 1 continued on next page
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found up-regulated in our RNA-seq analysis, also occured in the context of RXRAS427Y in JMSU-1
cells (Figure 1D), confirming gain-of-function with either aromatic substitution. Previous analysis of
human bladder cancer specimens identified a correlation between the presence of RXRAS427F/Y and
both the up-regulation of PLIN2 expression and PPAR signaling pathway activity (Cancer Genome
Atlas Research Network, 2014). Our data establishes a causal role of the RXRA mutations in driving
these expression changes.
Canonical RXRA-mediated gene regulation involves direct engagement of promoter/enhancers of
target genes in the context of homodimers or heterodimers. Specific partner-pairs preferentially
bind to direct repeats (DR) with defined spacer lengths. RXR homodimers and RXR/PPAR hetero-
dimers both show preference for DRs with a single nucleotide spacer (DR1) (Evans and Mangels-
dorf, 2014; Nielsen et al., 2008). Using ChIP-seq data for RXRA and acetylated H3K27 (H3K27ac),
we identified all active enhancer/promoters bound by RXRAwt and/or RXRAS427F in JMSU-1 (‘RXR-
bound Active Enhancer/promoters’ or RAEs). Differential mean peak height of the H3K27ac signal
was used as an indicator of relative activation status in the wild-type and mutant condition at each
RAE. ~12% of RAEs showed significant up-regulation in the mutant condition (FDR <0.05)
(Figure 1E, Figure 1—source data 2). HOMER motif finding was then performed to identify motifs
enriched at these hyper-activated RAEs, relative to the background of all RAEs. Consistent with acti-
vation of PPAR pathway genes, the canonical RXR/PPAR (DR1) motif was the only known motif found
to be enriched with significant q-value. The most statistically robust motif identified by de novo dis-
covery is shown in Figure 1E. Comparing the de novo identified motif to known motifs found it to
be most similar to a PPAR response element (DR1). These data demonstrate that hyper-activation of
enhancer/promoters driven by the RXRA hot-spot mutation occurs preferentially at canonical RXR/
PPAR response elements. Using transient transfection of a DR1-driven luciferase reporter, we con-
firmed relative hyper-activation of DR1 in the JMSU-1 cells expressing mutant RXRA compared to
wild-type (Figure 1F), with a degree of induction similar to that observed after pioglitazone
treatment.
Hot-spot mutation-driven transcriptional activity is dependent on
expression of PPARD or PPARG
Having established that mutant RXRA up-regulates PPAR target gene expression, we next tested if
this was dependent on PPARs. TCGA data were first queried to determine which of the three PPARs
are most highly expressed in bladder cancer specimens with mutant RXRA (Cerami et al., 2012).
Figure 1 continued
(FDR < 0.05) in cells expressing RXRAS427F compared to cells expressing RXRAwt were identified and then subjected to over representation analysis
(ORA, GO-Elite) to discover enriched pathways relative to all other protein coding transcripts identified by RNA-seq. Experiment was done in two
bladder cancer cell lines, JMSU-1 or 575A, using three RNA samples, each purified from an independent cell well, for each condition. (See also source
data 1). (C) Transcriptome changes induced by RXRAS427F relative to RXRAwt were compared to expression changes of the same transcripts induced by
16 hr of pioglitazone (1 mM) treatment in the RXRAwt expressing cells. D) Relative expression of two PPAR targets with expression of indicated RXRA
alleles. RT-qPCR performed in triplicate ±SD. Comparison by Student’s t-test. (E) RAEs were defined by the presence of overlapping ChIP-seq signal for
RXRA and H3K27ac. RAEs identified by binding of RXRAwt and/or RXRAS427F are represented in grey. Hyperactive RAEs represented in red had
elevated H3K27ac mean peak height in the mutant expressing cells compared to the wild-type cells (FDR < 0.05). All ChIP-seq peak callings were based
on data from three independent immuno-precipitations, each utilizing input material from an independent cell plate. HOMER motif analysis was used
to identify motifs enriched in hyperactive RAEs relative to the background of non-hyperactive RAEs. Source data 2 specifies number of peaks in each
sector of the venn diagram. (F) Activity of a DR1 response element reporter (3X PPRE) transfected into JMSU-1 cells stably expressing either RXRAwt or
RXRAS427F. RXRAwt cells were also treated with pioglitazone (1 mM) for 16 hr. For all reporter assays, Firefly luciferase expressing reporter was co-
transfected with a constitutive Renilla luciferase expression vector to normalize for transfection efficiency. Data represents mean ± SEM of Firefly to
Renilla luciferase signal from three independent experiments done on different days, each performed using triplicate cell wells. Statistical comparisons
are by paired t-test.
DOI: https://doi.org/10.7554/eLife.30862.003
The following source data is available for figure 1:
Source data 1. GO Elite Over Representation Analysis complete results.
DOI: https://doi.org/10.7554/eLife.30862.004
Source data 2. ChIP-seq peak numbers used to generate venn diagram in Figure 1E.
DOI: https://doi.org/10.7554/eLife.30862.005
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Both PPARG and PPARD were significantly more highly expressed than PPARA, but the relative pro-
portion of PPARG and PPARD varied amongst the samples (Figure 2A,B). Using siRNA, we acutely
knocked-down PPARG and PPARD in the JMSU-1 and 575A cells transduced with wild-type or
mutant RXRA and used RT-qPCR to query the expression of PLIN2 and FABP3 (Figure 2C). In the
non-targeting control, both genes were again found up-regulated by mutant RXRA. PPARD knock-
down alone appeared to increase PPARG expression suggesting receptor cross talk and loss of neg-
ative feedback regulation. However, expression of neither PPAR target gene was significantly
reduced by PPARD knock-down alone. PPARG knock-down partially inhibited PLIN2 expression in
both cell lines, but did not have significant impact on FABP3. Combined knock-down of PPARD and
PPARG, however, strongly inhibited RXRAS427F-driven hyper-expression of both genes, to an extent
greater than knockdown of PPARG alone. Thus, both PPARD and PPARG contribute to mutant
RXRA-mediated transcriptional hyperactivity in human bladder cancer cells and appear to have
redundant function.
Since hyperactivity of mutant RXRA was dependent on PPAR expression, we reasoned that no
hyperactivity would be observed in the DR-1 luciferase reporter assay in a bladder cancer cell line
with low endogenous expression of PPARs. Treatment of UM-UC-3 with agonists to either PPARG or
PPARD did not have meaningful impact on reporter activity when RXRA was transfected without a
PPAR (Figure 2D), indicating a lack of relevant endogenous expression in this cell line. Similarly,
RXRAS427F/Y did not show increased activity relative to RXRAwt (Figure 2D). Since RXRA can drive
transcription as a homodimer with a preference for the DR1 motif, these data indicate that the muta-
tion does not confer gain-of-function in the homodimer context. We then examined reporter activity
with co-transfection of PPARG or PPARD. Expression of either PPAR was sufficient to elicit mutant
RXRA associated hyperactivity to an extent that approximated agonist induced activation of the
PPAR in the wild-type RXRA condition (Figure 2D). Similar to what was observed in the JMSU-1 sta-
ble cells, RXRAS427F appeared to have somewhat stronger activity than RXRAS427Y, but both were
hyperactive relative to RXRAwt (Figure 2D). Lastly, we tested reporter activity with co-transfection of
retinoic acid receptor alpha (RARA), which belongs to another family of RXRA heterodimerization
partners. Both the DR1 reporter and a reporter with the preferred RXR/RAR binding motif, DR5,
were induced by the RAR agonist all-trans-retinoic acid, but mutant RXRA did not elicit greater activ-
ity than wild-type RXRA (Figure 2—figure supplement 1). These data confirmed that RXRA hot-
spot mutations confer gain-of-function selectively in the context of PPAR expression.
Mutant RXRA activates the PPAR AF2 via an allosteric mechanism
Nuclear receptors share a conserved domain structure and are prototypically activated by agonist
binding to the ligand-binding domain (LBD). The activator function two domain (AF2) is then stabi-
lized in a conformation favoring recruitment of co-activators, initiating transcriptional regulation. In
the context of RXRA/PPAR heterodimers, activation can be induced with agonists to either receptor
(Evans and Mangelsdorf, 2014). Solved crystal structures of the RXRA/PPARG heterodimer reveal
that RXRA S427 resides in helix 10 at a heterodimerization interface (Figure 3A) (Chandra et al.,
2008; Gampe et al., 2000). Based on its location, we hypothesized that the RXRA mutation directly
activates the PPARG AF2, independent of PPAR ligand binding. To gain evidence, we determined
the inducibility of PPARG Q286P, a previously characterized substitution in the ligand-binding
pocket (Figure 3A) that prevented ligand activation by a panel of PPARG agonists (Walkey and
Spiegelman, 2008). The Q286P mutation completely blocked pioglitazone-driven receptor activa-
tion, but RXRA S427F-driven receptor hyperactivity was maintained (Figure 3B). In contrast, the
PPARG E471A mutation previously characterized to diminish the transactivation activity of the
PPARG AF2 (Chen et al., 2000), strongly reduced both pioglitazone and RXRA S427F-driven activity
(Figure 3B). The analogous AF2 mutation in RXRA, E453A, diminished activation by the RXRA ago-
nist SR11237, but had no impact on mutation-driven hyperactivity (Figure 3C). These data support a
model in which RXRAS427F hyperactivity relies primarily on the PPAR AF2, independent of PPAR ago-
nist binding.
To gain insight into how RXRAS427F/Y regulates the PPARG AF2, we performed long-time scale
molecular simulations of RXRA/PPARG heterodimers with wild-type RXRA or after the S427F substi-
tution. The starting structure was the agonist-bound crystal structure of the RXRA/PPARG LBDs
(PDB: 1FM6) (Gampe et al., 2000); however, the agonist compounds were deleted to reduce subse-
quent computational complexity and to enable drift toward the inactivated state. We next
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Figure 2. PPARG or PPARD expression is necessary and sufficient for mutant RXRA activity. A) PPAR RNA expression in RXRA hot-spot mutant clinical
samples from the TCGA dataset. Whisker plot shows 25th, median, and 75th percentile. (B) Data from panel A plotted per patient with hot-spot
mutation. (C) Effects of siRNA-mediated knock-down of PPARD and PPARG in JMSU-1 and 575A cell lines on two target genes (PLIN2 and FABP3) up-
regulated by mutant RXRA. Data by RT-qPCR in triplicate ±SD and indicated comparisons by Student’s t-test. (D) DR1 luciferase reporter activity in UM-
Figure 2 continued on next page
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constructed Markov State Models (MSMs) following the procedure from Hart et al. (2016) to quan-
tify the thermodynamics and kinetics of each heterodimer. First, conformations adopted by back-
bone-heavy atoms near the mutated site in RXRA and the PPARG AF2 (RXRA 425–429 and PPARG
445–477) from both wild-type and mutant simulations were clustered in the same state space. An
MSM was then constructed for each variant based on how often the corresponding simulations tran-
sitioned between every pair of clusters. The wild-type and mutant largely populate different clusters,
consistent with our hypothesis that mutant and wild-type RXRA differentially regulate the PPARG
AF2 region (Figure 3—figure supplement 1A)
We next inspected the three most frequently occupied clusters for wild-type and mutant by
superimposing the PPARG residues 445–459 on helix 11 as an anchor, enabling us to visualize rela-
tive displacement of the AF2 region located in helix 12 (Figure 3D). In the RXRA mutant condition,
PPARG E471 more closely approximated the agonist confirmation, in agreement with our mutational
studies showing the importance of this residue. The terminal tyrosine of PPARG (Y477) also
appeared in distinct spaces in the two conditions. Comparing the 5% most frequently occupied clus-
ters for wild type and mutant, we observed a significant difference in inter-residue distance between
RXRA 427 and PPARG 477 (Figure 3E). These data raised the possibility that an aromatic interaction
between RXRA S427F/Y and the terminal tyrosine found in all PPARs may underlie activation of
PPAR (Figure 3F). To test this, the terminal tyrosine was either deleted or mutated to serine in both
PPARG (Y477) and PPARD (Y441) and expression of the mutant PPARs was confirmed by western
blot (Figure 3—figure supplement 1B). Inducibility by RXRAS427F or agonist was then determined
(Figure 3B and G). In all cases, inducibility by agonist was maintained, but RXRA S427F-mediated
hyperactivity was eliminated. We conclude that S427F/Y initiates an allosteric relay via an aromatic
interaction with the terminal tyrosine on PPAR, leading to PPAR AF2 activation. No other RXR dimer-
ization partners have an aromatic amino acid at the corresponding position, providing a structural
basis for the selective activation of PPARs (Figure 3F).
PPARD activation induces growth-factor-independent growth of
urothelial organoids in the context of tumor suppressor loss
We next sought to determine if PPAR activation drives proliferation of urothelial cells. To culture pri-
mary urothelial cells, we developed a mouse urothelial organoid culture system. Similar organoid
systems have proven successful at identifying pro-tumorigenic phenotypes driven by cancer-associ-
ated mutations in multiple tissue types (Sachs and Clevers, 2014; Karthaus et al., 2014;
Drost et al., 2015; Hwang et al., 2016; Boj et al., 2015). With our urothelial approach, hollow
spherical epithelial structures can reliably be grown and passaged from primary mouse bladder epi-
thelium, utilizing epidermal growth factor (EGF) as the primary growth factor (Figure 4—figure sup-
plement 1A). Because growth-factor-independent growth is a classical hallmark of transformed cells,
we asked if stimulation with PPAR agonists could confer growth in the absence of EGF. As expected,
there was no growth of three independently derived wild-type organoids in the absence of growth
factor. Treatment with the PPARD agonist GW0742 or the PPARG agonist pioglitazone had no sig-
nificant effect on growth in these conditions, suggesting that PPAR activation is not sufficient to
drive growth in normal urothelial organoids (Figure 4A).
Bladder cancer genomes typically harbor mutations in several genes recognized as recurrently
altered in bladder cancers (Cancer Genome Atlas Research Network, 2014). We speculated that
pro-tumorigenic activities of PPAR signaling may only be apparent in the context of tumor suppres-
sor loss. For our analysis, we focused on TP53 and KDM6A which are amongst the most frequently
Figure 2 continued
UC-3 cells transfected with RXRA ±PPARD or PPARG. Cells were treated with 1 mM of the PPARG agonist pioglitazone or the PPARD agonist GW0742
for 16 hr. Data represents mean ±SEM of Firefly to Renilla luciferase signal from three independent experiments done on different days, each
performed using triplicate cell wells. Statistical comparisons are by paired t-test.
DOI: https://doi.org/10.7554/eLife.30862.006
The following figure supplement is available for figure 2:
Figure supplement 1. RARA expression is not sufficient for mutant RXRA hyperactivity.
DOI: https://doi.org/10.7554/eLife.30862.007
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Figure 3. Mutant RXRA induces allosteric activation of PPARs through their terminal tyrosine. A) RXRA S427 and other amino acids mutated for
structure-function studies highlighted in green on a published full-length crystal structure of a RXRA/PPARG heterodimer. (B) DR1 reporter assay in UM-
UC-3 co-transfecting indicated RXRA and PPARG alleles. Cells were treated with vehicle (DMSO) or pioglitazone 1 mM for 16 hr. Data represents mean
normalized signal ±SEM of three independent experiments done on different days, each performed in triplicate, with data from each experiment
Figure 3 continued on next page
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mutated tumor suppressors in bladder cancer, mutated in ~50% and~25% of bladder cancer cases,
respectively (Cancer Genome Atlas Research Network, 2014; Guo et al., 2013; Van Allen et al.,
2014). Of 16 patient samples identified with an RXRA hot-spot mutation across three cohorts, four
had mutations in both TP53 and KDM6A, five had mutations in TP53 only, three had mutations in
KDM6A only, and four had mutations in neither (Cerami et al., 2012). To determine if loss of tumor
suppressor function would enable pro-tumorigenic activities of PPAR activation, we generated con-
ditional knock-out bladder organoids from mice with the following three genotypes: (1) Trp53F/F, (2)
Kdm6aF, and (3) Trp53F/F;Kdm6aF. Three independent organoid lines (each from a distinct mouse
bladder) were generated with each genotype. These organoid lines were then all infected with
Adeno-cre and complete deletion of the conditional alleles was confirmed by genotyping PCR (not
shown). The wild-type organoids utilized in Figure 4A were generated from the littermates of these
mice and also were infected with Adeno-Cre to control for Cre exposure.
We then determined growth of the organoids in EGF deplete media after treatment with PPAR
agonists (Figure 4B, Figure 4—figure supplement 1B). No genotype showed consistent positive
growth in the vehicle condition. Elimination of Trp53, but not Kdm6a, was sufficient for GW0742 to
drive proliferation. With combined knock-out of Trp53 and Kdm6a, growth induction by GW0742
was even more robust than with Trp53 knock-out alone. These data suggest that loss of tumor sup-
pressors creates a context permissive for PPARD-driven proliferation. Even though responsiveness
to GW0742 was consistent across all of the dual knock-out organoids, we reasoned that utilizing a
clonal sub-line might minimize variation due to random clonal skewing in later experiments involving
retroviral infection and drug selection. Therefore, we established DKO 431.A from a single organoid
picked from the DKO 431 line and assessed its responsiveness to PPAR agonists. DKO 431.A
showed strong, dose-dependent, enhanced growth when treated with GW0742, but not pioglita-
zone (Figure 4C). To assess transcriptional activation by the same PPAR agonists, DKO 431.A orga-
noids were plated in standard media for 7 days and then treated with two doses of GW0742 or
pioglitazone for 48 hr. Expression of two PPAR target genes, Plin2 and Fabp4 was then determined
by RT-qPCR. GW0742 strongly induced both genes, while pioglitazone and little to no effect
(Figure 4D, Figure 4—figure supplement 1C). These findings confirm that the ability of PPAR ago-
nists to induce target genes in DKO 431.A correlates with their ability to promote growth-factor-
independent growth. The apparent lack of response to PPARG agonist in these experiments is likely
simply due to its lower expression in these mouse organoids relative to 575A and JMSU-1, the two
cells lines in which we had established induction of PPAR target genes with pioglitazone in Figure 1
(Figure 4—figure supplement 1D).
Mutant RXRA drives sustained growth-factor-independent growth in
urothelial organoids with concurrent loss of Kdm6a and Trp53
We then asked if RXRAS427F would promote growth-factor-independent growth. DKO 431.A was
infected with retrovirus bearing empty vector, RXRAwt, or RXRAS427F and similar expression levels of
RXRA between the wild-type and mutant condition was confirmed by western blot and qPCR
(Figure 4E). Growth of the organoids in EGF deplete media was then assessed. Mutant RXRA-
Figure 3 continued
normalized to the RXRAwt vehicle condition for each section. Statistical comparisons are by unpaired t-test. (C) Left, reporter assay performed with
indicated RXRA alleles only and drug treatment with the RXRA agonist SR11237 (100 nM) for 16 hr. Right, reporter assay with wild-type PPARG co-
transfected. Data represent mean ±SEM of Firefly to Renilla luciferase signal from three independent experiments done on different days, each
performed using triplicate cell wells. Statistical comparisons are by paired t-test. (D) Published agonist structure of RXRA/PPARG heterodimer (PDB:
1FM6) in red and blue with key residues highlighted in bright green. Top three occupied microstate clusters from simulation experiments are
superimposed. (E) Distance from starting agonist structure between alpha carbons of RXR 427 and PPARG 477 in the top 5% most-occupied
microstates for wild-type and mutant RXRA. Mean ±SD, comparison is by Student’s t test. (F) Alignment of the AF2 region and C-terminus of all RXRA
dimerization partners. Terminal tyrosine unique to PPARs is indicated. (G) Reporter assay similar to B, but using PPARD and the PPARD agonist
GW0742.
DOI: https://doi.org/10.7554/eLife.30862.008
The following figure supplement is available for figure 3:
Figure supplement 1.
DOI: https://doi.org/10.7554/eLife.30862.009
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Figure 4. PPARD agonist and mutant RXRA confer growth-factor-independent growth to urothelium in the context of tumor suppressor loss. (A)
Organoids were derived from three independent wild-type mouse bladders and infected with Adeno-Cre. Growth was determined for each line in
organoid media without EGF using CellTiter-Glo after treatment with vehicle, GW0742 (100 nM), or pioglitazone (100 nM). Data represent mean ±SEM
from three independent experiments, each performed in triplicate cell wells. Statistical comparison is by unpaired t-test. (B) Similar to A but organoids
Figure 4 continued on next page
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expressing organoids grew significantly faster than empty vector or wild-type expressing organoids
(Figure 4F). However, growth was also observed in the wild-type condition. To ensure that the dif-
ference between mutant and wild-type growth was robust, we passaged wild-type and mutant-
expressing organoids with tyrpsinization weekly, always plating an identical number of cells and then
counting the number of cells present at time of each passage. The total number of doublings over
six passages was then determined. Mutant RXRA organoids showed consistent growth throughout
the experiment, while the wild-type condition appeared to plateau (Figure 4G). Comparing the
number of doublings per passage between the two conditions, we found the difference to be highly
significant (paired t test p=0.0003), confirming gain-of-function with the mutant allele.
Mutant RXRA-driven proliferation of urothelial organoids is dependent
on PPARD activity
Having established that RXRAS427F phenocopies GW0742 induced growth in the organoid growth
assay, we next looked for transcriptional evidence that RXRAS427F was activating PPARD. Organoids
were cultured in standard media for seven days and then treated with PPAR antagonists for an addi-
tional two days. We then determined mRNA expression levels of two PPAR target genes by RT-
qPCR. Comparing vehicle-treated samples, Plin2 and Fabp4 were found significantly up-regulated in
the mutant condition compared to the empty vector or wild-type organoids, confirming that mutant
RXRA up-regulates expected PPAR targets in the organoid system (Figure 5A). Treatment of the
mutant expressing organoids with either of two PPARD inverse agonists, ST247 and GSK0660,
blunted up-regulation of the target genes (Figure 5A, Figure 5—figure supplement 1)
(Naruhn et al., 2011; Shearer et al., 2008). The PPARG antagonist T0070907 did not show any
inhibitory activity. These findings confirm that mutant RXRA drives PPARD hyper-activity in the orga-
noid system.
We next sought to determine if mutant RXRA-driven growth could be reversed with PPAR inhibi-
tion. When treated with either of the two PPARD antagonists, the mutant expressing organoids
showed significant, dose-dependent growth inhibition (Figure 5B.) To determine if the proliferative
effects of PPARD inhibitors was specific to the RXRA-mutant-driven proliferation, we utilized an
organoid line we established from a carcinogen-induced bladder tumor, called MCB6C, which shows
robust growth in EGF deplete media, but does not harbor the RXRA mutation (not shown). Treat-
ment of MCB6C with the PPARD inhibitors in EGF deplete media did not inhibit their growth across
the identical doses (Figure 5C). As expected based on the gene expression analysis, the PPARG
antagonist T0070907 also had no antiproliferative effects on 431.A.RXRAS427F (Figure 5D). Lastly,
431.A.RXRwt organoids in EGF-containing media were treated with the same PPAR antagonists,
none of which significantly inhibited growth of this organoid line (Figure 5E), confirming PPAR
dependence is specific to mutant RXRA-driven proliferation.
Figure 4 continued
were derived from Trp53flox/flox; Kdm6aflox mice. (C) CellTiter-Glo growth assay in media without EGF of a sub-clone from DKO431 (DKO 431.A) treated
with GW0742 (10, 100 nM) or pioglitazone (100, 1000 nM). Mean values ± SEM from three independent experiments, each performed using triplicate
organoid wells. Comparison is by paired t-test. (D) DKO 431.A organoids were plated in standard organoid media and then treated with, vehicle,
GW0742 (10, 100 nM)) or pioglitazone (100, 1000 nM) for an additional 48 hr. Induction of PPAR target genes was determined by RT-qPCR in
triplicate ± SD. (See also Figure 4—figure supplement 1C.) (E) DKO 431.A organoids were infected with a retroviral vector that was empty, expresses
RXRAwt, or expresses RXRAS427F and expression of total RXRA (western blot) and human RXRA (RT-qPCR, triplicate +/SD) was determined. (F) Mean
CellTiter-Glo signal ±SEM from three identical experiments, each performed using triplicate organoid wells. Comparison of D10 data is by paired t-test.
(G) Identical number of indicated organoid cells were plated in media without EGF and then harvested with trypsin weekly and counted in duplicate
using a BioRad TC20. Identical numbers of cells were then re-plated and this was repeated for 6 weeks. Total cell number doublings were calculated
and plotted. Comparison of doublings is by paired t-test.
DOI: https://doi.org/10.7554/eLife.30862.010
The following figure supplement is available for figure 4:
Figure supplement 1.
DOI: https://doi.org/10.7554/eLife.30862.011
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Figure 5. RXRA S427F generates PPARD-dependent urothelial growth. (A) Retrovirally transduced organoids from Figure 4 were plated for 7 days in
standard media and then treated with the indicated PPARD antagonists (1000 nM ST-247, GSK0660) or PPARG antagonist (100 nM T0070907) for 2 days.
Expression of PPAR targets was determined by RT-qPCR in triplicate ±SD and comparison is by Student’s t-test to the RXRAS427F DMSO condition. (See
also Figure 5—figure supplement 1)) (B-E) CellTiter-Glo growth assay of indicated organoid lines treated with indicated drugs. Plotted is mean
Figure 5 continued on next page
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Discussion
A role for PPAR activity in promoting bladder cancer is supported by the presence of a PPARG gene
amplification in 17% of cases (Cancer Genome Atlas Research Network, 2014). Intriguingly, piogli-
tazone use in patients with diabetes appears to increase bladder cancer risk, further hinting that
PPARG activation can promote bladder cancer growth (Lewis et al., 2011). Our studies identified
RXRA point mutations as a second genomic mechanism by which PPARs can be hyperactivated.
These data, along with our direct functional evidence that PPAR activation by agonist or mutant
RXRA drives urothelial proliferation, build on a growing body of data credentialing PPARs as bladder
cancer drivers. Importantly, human bladder cancer samples appear to express both PPARD and
PPARG and our data suggest both are activated by mutant RXRA and play a role in transcriptional
hyperactivity in human bladder cancer cells. In order to guide drug development, future studies will
be needed with a broad panel of human-derived tissue to determine if one PPAR isoform is of
greater clinical relevance to RXRA mutation-driven disease. We speculate co-targeting of PPARD
and PPARG will be necessary, perhaps even in PPARG amplified cases, as functional redundancy of
homologous nuclear receptors or kinases is known to be exploited by tumors, in some cases underly-
ing treatment resistance to therapeutics targeting only one homologue (Arora et al., 2013;
Juric et al., 2015).
Heyman and colleagues showed two decades ago that RXR agonists can induce activation of
RXR/PPAR heterodimers, independent of the RXR AF2, by inducing conformational changes in PPAR
(Schulman et al., 1998). The RXRA hot-spot mutations appear to co-opt a similar, although mecha-
nistically distinct, activation principle, relying on the introduction of an aromatic interaction that
drives ligand-independent activation of PPARs. While this manuscript was under preparation, Korpal
et al. reported biophysical data characterizing the mutant RXRA/PPARG heterodimer (Korpal et al.,
2017). Those in vitro findings align with our modeling predictions, which we further functionally vali-
dated with cell-based mutational studies, both with PPARG and PPARD. This allosteric activation
mechanism of the PPAR AF2 by mutant RXRA raises unique challenges with regard to inhibitor
design. In our study, we utilized inverse agonists which bind the LBD and stabilize interactions with
co-repressors. While they are effective at reversing mutant RXRA-driven activity, we suspect chemi-
cal screens using assays in which PPARs are activated through the mutation-based mechanism may
identify optimal inverse agonists capable of more complete target inhibition.
Inverse agonists binding the PPAR LBD remain the most characterized strategy to inhibit PPAR
activity, but may not prove to be the most effective approach for blocking ligand independent activ-
ity driven by RXRA mutations. A potentially more effective strategy might be through the identifica-
tion of small molecules that induce PPAR degradation. Supporting the concept, ligands that induce
destabilizing conformations in ER have been identified (Wu et al., 2005), and the clinical utility of
the ER degrader fluvestrant has been validated in breast cancer clinical trials (Howell et al., 2002;
Osborne et al., 2002). Similar to ER, PPARs undergo agonist-induced degradation, suggesting ther-
apeutic ligand-induced degradation of PPARs might also be feasible (Hauser et al., 2000). Perhaps,
a more rational approach to inducing PPAR degradation would be to engineer PPAR ligands linked
to a chemical tag (e.g. PROTAC) that targets proteins to the proteasome. Such approaches have
been used in preclinical systems to degrade other nuclear receptors (Rodriguez-Gonzalez et al.,
2008), although the clinical utility of the approach is not yet established. Lastly, the identification of
biologically active small molecules that disrupt co-regulator binding to the ER AF2 raises yet another
possible paradigm for targeting ligand-independent activation through the identification of small
Figure 5 continued
signal ±SEM from three independent experiments, each performed using triplicate organoid wells. MCB6C is an organoid line we derived from a
carcinogen-induced bladder tumor and lacks RXRA mutation. Organoids were cultured in media without EGF except for panel E where inclusion of
EGF is indicated. Comparison is to DMSO condition using paired t-test.
DOI: https://doi.org/10.7554/eLife.30862.012
The following figure supplement is available for figure 5:
Figure supplement 1. Aggregated RT-qPCR from three distinct experiments as described in Figure 5A with each data point from each experiment
plotted with mean indicated.
DOI: https://doi.org/10.7554/eLife.30862.013
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molecules that recognize the activated PPAR AF2 (Raj et al., 2017). Our work here should encour-
age such approaches with the goal of identifying inhibitors that effectively overcome PPAR tumori-
genic activity due to PPARG amplification and RXRA mutation.
The organoid system provided us with a unique capability to assay epithelial autonomous effects
of PPAR activity in defined genetic contexts, including normal urothelium. In contrast to classical
growth factors such as EGF which stimulate proliferation of wild-type organoids, we found that
PPARD activation is only sufficient to drive growth with concurrent tumor suppressor loss. One possi-
ble explanation is that tumor suppressor loss alters PPARD-driven transcriptional regulation. Studies
with AR in prostate cancer suggest that the AR cistrome is broadly reprogrammed during tumori-
genesis (Pomerantz et al., 2015), supporting a model in which nuclear receptors take on de novo
target regulation in transformed cells. Alternatively, tumor suppressor loss may alter the cellular
response to PPARD activation and/or provide complementary pro-tumorigenic signals. These possi-
bilities will be explored in future studies and should help elucidate the cellular mechanisms by which
PPAR signaling can drive urothelial proliferation. Regardless of the underlying mechanisms, however,
our findings, along with recent work from others demonstrating PPARG orchestrates an immunosup-
pressive micro-environment to enhance tumor growth in vivo (Korpal et al., 2017), provide an
increasingly compelling rationale for the development of a new class of molecularly targeted drugs




or resource Designation Source or reference Identifiers Additional information
gene (Homo sapiens) RXRA NA NCBI Gene ID:6256;
NM_002957
gene (H. sapiens) PPARG NA NCBI Gene ID:5468;
NM_138711




Kdm6aF other Generated by Dr. Lukas Wartman
(Washington University School of
Medicine) with ES cells obtained















cell line (M. musculus) MCB6C this paper Clonal organoid line generated
from tumor bearing bladder of male
C57BL/6 mouse treated with BBN
cell line (M. musculus) DKO 431.A this paper clonal organoid line generated
from the urothelium of a male
Trp53Flox/Flox;Kdm6aFlox mouse
cell line (M. musculus) WT this paper Organoid lines generated from the
urothelium of wild-type male mice
resulting from cross between
Trp53Flox/+ and Kdm6aFlox/+ mice
cell line (M. musculus) "Trp53-/-;
Kdm6a-"; DKO
this paper Organoid lines were generated
from the urothelium of Trp53Flox/Flox;
Kdm6aFlox male mice and then
infected with Ad5CMVCre-eGFP
adenovirus in vitro
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Reagent type (species)
or resource Designation Source or reference Identifiers Additional information
cell line (M. musculus) "Kdm6a-"; KKO this paper Organoid lines were generated
from the urothelium of Kdm6aFlox
male mice and then infected with
Ad5CMVCre-eGFP adenovirus in vitro
cell line (M. musculus) "Trp53-/-"; PKO this paper Organoid lines were generated
from the urothelium of Trp53Flox/Flox
male mice and then infected with
Ad5CMVCre-eGFP adenovirus in vitro
cell line (M. musculus) DKO 431.A.EV this paper DKO 431.A organoid line infected
with retrovirus carrying
pBABE puro empty vector
cell line (M. musculus) DKO 431.
A.RXRAwt
this paper DKO 431.A organoid line infected
with retrovirus
carrying pBABE puro RXRA
cell line (M. musculus) DKO 431.A.RXRAS427F this paper DKO 431.A organoid line infected
with retrovirus carrying
pBABE puro RXRA S427F
cell line (H. sapiens) JMSU-1 other RRID:CVCL_2081 obtained from Dr. David
Solit (MSKCC)
cell line (H. sapiens) 575A other RRID:CVCL_7941 obtained from Dr. David
Solit (MSKCC)
cell line (H. sapiens) UM-UC-3 other RRID:CVCL_1783 obtained from Dr. David
Solit (MSKCC)
cell line (H. sapiens) Lenti-X 293T Clontech Clontech:632180
cell line (H. sapiens) JMSU-1 RXRA WT this paper JMSU-1 cell line infected with
retrovirus carrying
pBABE puro RXRA
cell line (H. sapiens) JMSU-1 RXRA S427F this paper JMSU-1 cell line infected
with retrovirus carrying
pBABE puro RXRA S427F
cell line (H. sapiens) JMSU-1 RXRA S427Y this paper JMSU-1 cell line infected with
retrovirus carrying
pBABE puro RXRA S427Y
cell line (H. sapiens) 575A RXRA WT this paper 575A cell line infected with
retrovirus carrying
pBABE puro RXRA
cell line (H. sapiens) 575A RXRA S427F this paper 575A cell line infected with
retrovirus carrying
pBABE puro RXRA S427F
antibody anti-PPARG (81B8)
(rabbit monoclonal)
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Reagent type (species)
or resource Designation Source or reference Identifiers Additional information
antibody anti-mouse IgG,
HRP (horse)















recombinant DNA reagent PPRE X3-TK-luc;
DR1 reporter
(plasmid)
Addgene; PMID 9539737 Addgene:1015 plasmid was deposited
by Bruce Spiegelman
recombinant DNA reagent pGL3-RARE-luciferase;
DR5 reporter (plasmid)
Addgene; PMID 16818722 Addgene:13458 plasmid was deposited
by T. Michael Underhill
recombinant DNA reagent pRL-SV40 (plasmid) Promega Promega:E2231
recombinant DNA reagent pCL-ampho (plasmid) other obtained from
Dr. Charles Sawyers (MSKCC)
recombinant DNA reagent VSVG (plasmid) other obtained from
Dr. Charles Sawyers (MSKCC)
recombinant DNA reagent pCMV6-XL4 RARA
(plasmid)
OriGene OriGene:SC119566
recombinant DNA reagent pCMV6-XL4 PPARG
(plasmid)
OriGene OriGene:SC108192
recombinant DNA reagent pCMV6-XL4 PPARG
Q286P (plasmid)
this paper Q286 was mutated via site-directed
mutagenesis of pCMV6-XL4 PPARG
recombinant DNA reagent pCMV6-XL4 PPARG
E471A (plasmid)
this paper E471 was mutated via site-directed
mutagenesis of pCMV6-XL4 PPARG
recombinant DNA reagent pCMV6-XL4 PPARG
Y477S (plasmid)
this paper Y477 was mutated via site-directed
mutagenesis of pCMV6-XL4 PPARG
recombinant DNA reagent pCMV6-XL4 PPARG
Y477X (plasmid)
this paper Y477 was deleted via site-directed
mutagenesis of pCMV6-XL4 PPARG
recombinant DNA reagent pCMV6-XL4 empty
vector (plasmid)
this paper generated by digesting pCMV6-XL4
PPARG with NotI to remove PPARG
and by ligating the plasmid ends
with T4 DNA ligase
recombinant DNA reagent pBABE puro
RXRA (plasmid)
Addgene Addgene:11441 deposited by Ronald Kahn
recombinant DNA reagent pBABE puro RXRA
S427F (plasmid)
this paper S427 was mutated via site-directed
mutagenesis of pBABE puro empty vector
recombinant DNA reagent pBABE puro RXRA
S427Y (plasmid)
this paper S427 was mutated via site-directed
mutagenesis of pBABE puro empty vector
recombinant DNA reagent pBABE puro RXRA
E453A (plasmid)
this paper E453 was mutated via site-directed
mutagenesis of pBABE puro empty vector
recombinant DNA reagent pBABE puro RXRA
S427F/E453A (plasmid)
this paper E453 was mutated via site-directed
mutagenesis of pBABE puro RXRA S427F
recombinant DNA reagent pBABE puro empty
vector (plasmid)
this paper generated by digesting pBABE
puro RXRA with EcoRI to remove
RXRA and by ligating the plasmid
ends with T4 DNA ligase
recombinant DNA reagent pCMV6-XL4 PPARD
(plasmid)
this paper Human PPARD was cloned
from JMSU-1 epithelial bladder
cancer cells and inserted
into the pCMV6-XL4
recombinant DNA reagent pCMV6-XL4 PPARD
Y441S (plasmid)
this paper Y441 was mutated via site-directed
mutagenesis of pCMV6-XL4 PPARD
Continued on next page
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Reagent type (species)
or resource Designation Source or reference Identifiers Additional information
recombinant DNA reagent pCMV6-XL4 PPARD
Y441X (plasmid)
this paper Y441 was deleted via site-directed














commercial assay or kit Dual-Glo Luciferase
Assay System
Promega Promega:E2940
commercial assay or kit CellTiter-Glo Promega Promega:G7571
commercial assay or kit Ovation Ultraflow
System V2
NuGen NuGen:0344-32
chemical compound, drug Pioglitazone Sigma-Aldrich Sigma-Aldrich:E6910
chemical compound, drug GW 0742 Tocris Tocris:2229
chemical compound, drug SR 11237 Tocris Tocris:3411
chemical compound, drug all-trans-Retinoic
Acid (ATRA)
Sigma-Aldrich Sigma-Aldrich:R2625
chemical compound, drug GSK 0660 Tocris Tocris:3433
chemical compound, drug ST247 Sigma-Aldrich Sigma-Aldrich:SML0424
chemical compound, drug T0070907 Cayman Chemical Cayman Chemical:10026
software, algorithm GROMACS 5.1.3 DOI: 10.1016/j.softx.
2015.06.001
RRID:SCR_014565
software, algorithm MSMBuilder 2.8 PMID: 22125474












this paper 5’ CTGGCAGGATATGATA
GCAATGTG 3’
sequence-based reagent

























this paper 5’ CTGCTCCATGGCT
GATCTCC 3’
sequence-based reagent
PPARG fwd1 (primer) this paper 5’ ATGCCTTGCAGT
GGGGATGTC 3’
sequence-based reagent
PPARG rev1 (primer) this paper 5’ GAGGTCAGCGGA
CTCTGGATTC 3’
Continued on next page
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sequence-based reagent
hPLIN2 fwd1 (primer) this paper 5’ AGTGCTCTGCCC
ATCATCCAG 3’
sequence-based reagent
hPLIN2 rev1 (primer) this paper 5’ TCACAGCGCCTT
TGGCAT TG 3’
sequence-based reagent
FABP4 fwd1 (primer) this paper 5’ ACTGCAGCTTCCT
TCTCACCTTG 3’
sequence-based reagent
FABP4 rev1 (primer) this paper 5’ TGCCAGCCACTT
TCCTGGTG 3’
sequence-based reagent
mPlin2 Fwd1 (primer) this paper 5’ GTGCCCTGCCC
ATCATCC 3’
sequence-based reagent
mPlin2 Rev1 (primer) this paper 5’ TTACGGCACCTCT
GGCACTG 3’
sequence-based reagent
mFabp4 Fwd1 (primer) this paper 5’ TGCAGCCTTTCTCA
CCTGGAAG 3’
sequence-based reagent
mFabp4 Rev1 (primer) this paper 5’ GCCTGCCACTTTCC
TTGTGG 3’
sequence-based reagent
RXRA fwd1 (primer) this paper 5’ ACAAGACGGAGC
TGGGCTG 3’
sequence-based reagent
RXRA rev2 (primer) this paper 5’ GGCTGCTCTGGGT
ACTTGTGC 3’
sequence-based reagent
RXRA E453A SDM For
(primer)
this paper 5’ acaccttccttatggccat
gctggaggcgccg 3’
sequence-based reagent
RXRA E453A SDM Rev
(primer)
this paper 5’ cggcgcctccagcatggcc
ataaggaaggtgt 3’
sequence-based reagent RXRa S427F-F (primer)
this paper 5’ CCG GCT CTG CGC TTT
ATC GGG CTC AAA T 3’
sequence-based reagent
RXRa S427F-R (primer) this paper 5’ CAT TTG AGC CCG ATA
AAG CGC AGA GCC G 3’
sequence-based reagent
RXRa S427Y-F (primer) this paper 5’ CCG GCT CTG CGC TAT
ATC GGG CTC AAA T 3’
sequence-based reagent
RXRa S427Y-R (primer) this paper 5’ CAT TTG AGC CCG ATA
TAG CGC AGA GCC G 3’
sequence-based reagent
F hPPARGQ286P (primer) this paper 5’ ccacggagcgaaacgg
gcagccctgaaag 3’
sequence-based reagent
R hPPARGQ286P (primer) this paper 5’ ctttcagggctgcccgttt
cgctccgtgg 3’
sequence-based reagent
F hPPARGE471A (primer) this paper 5’ agtccttgtagatcgcctg
caggagcggg 3’
sequence-based reagent
R hPPARGE471A (primer) this paper 5’ cccgctcctgcaggcgat
ctacaaggact 3’
sequence-based reagent
PPARG Y477S For SDM
(primer)
this paper 5’ GAGATCTACAAGGACTTGAG
CTAGCAGAGAGTCCTGAGC 3’
sequence-based reagent
PPARG Y477S Rev SDM
(primer)
this paper 5’ GCTCAGGACTCTCTGCTAGCT
CAAGTCCTTGTAGATCTC 3’
sequence-based reagent
PPARG Y477X For SDM
(primer)
this paper 5’ GATCTACAAGGACTTGTAG
TAGCAGAGAGTCCTGA 3’
sequence-based reagent
PPARG Y477X Rev SDM
(primer)
this paper 5’ TCAGGACTCTCTGCTACTAC
AAGTCCTTGTAGATC 3’
sequence-based reagent
PPARD Y441S For (primer) this paper 5’ AGATCTACAAGGACATGAG
CTAACGGCGGCACCCAG 3’
sequence-based reagent
PPARD Y441S Rev (primer) this paper 5’ CTGGGTGCCGCCGTTA
GCTCATGTCCTTGTAGATCT 3’
Continued on next page
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sequence-based reagent
PPARD Y441X For (primer) this paper 5’ GATCTACAAGGACATGTGA
TAACGGCGGCACCCAGG 3’
sequence-based reagent
PPARD Y441X Rev (primer) this paper 5’ CCTGGGTGCCGCCGTTATC
ACATGTCCTTGTAGATC 3’
Mouse Bladder Organoid Generation and Culturing: Urothelium was dissected from bladders col-
lected from 6- to 8-week-old male mice, minced into smaller pieces with scissors, and digested with
collagenase type II (17101015 Gibco) re-suspended at 5 mg/mL in Advanced DMEM/F12++
+ medium (advanced DMEM/F-12 medium (12634028 Gibco) supplemented with 1% penicillin-strep-
tomycin and 1% HEPES (MT25060CI Corning)), 5 mM ROCK1/2 inhibitor Y-27632 (72302 Stemcell
Technologies), and 0.2 mg/mL elastase (E7885 Sigma) for 4 hr at 37˚C while shaking at 700 rpm.
After digestion with collagenase, cells were pelleted at 500 x g for 5 min and digested with TrypLE
(12605010 Gibco) for 30 min at 37˚C with shaking at 700 rpm. Cells were washed with Advanced
DMEM/F12+++ medium and re-suspended in growth factor reduced Matrigel (356231 Corning) at
10,000 cells per a 50 mL Matrigel tab. Tabs were incubated at 37˚C for 15 min to allow Matrigel to
harden. Once hardened, tabs were cultured in organoid medium prepared as described in
Gao et al. (2014) except for the following changes: final concentration of EGF was 5 ng/mL, final
concentration of A83-01 was 20 nM, and FGF10, FGF2, dihydrotestosterone, Y-27632, SB202190,
and primocin were omitted. Organoids were split approximately every 7 days. Tabs were homoge-
nized by pipetting. Organoids were digested with TrypLE for approximately 20 min at 37˚C with
periodic vortexing. Cells were washed with Advanced DMEM/F12+++ medium and re-suspended at
10,000 cells per a 50 mL Matrigel tab. To generate MCB6C, mice were treated with BBN 0.1% via
drinking water for 22 weeks. Bladders were harvested and a polyclonal organoid line (MCB6) was
generated from a tumor-bearing bladder. A single organoid was isolated to generate MCB6C.
Mice
Animals were handled and housed according to protocols approved by the Washington University
School of Medicine Institutional Animal Care and Use Committee. Kdm6aF mice were generated by
Dr. Lukas Wartman (Washington University School of Medicine) with ES cells obtained from
EUCOMM with the Kdm6atm1a(EUCOMM)Wtsi allele (manuscript in preparation) and maintained on the
C57BL6/J background. B6.129P2-Trp53tm1brn/J (Trp53Flox) mice were purchased from Jackson Labo-
ratory (stock # 008462). Mice were genotyped via PCR (Kdm6a 5’ CGAGAAAGGAAATGTGAGAG-
CAAGG 3’ and 5’ CTGGCAGGATATGATAGCAATGTG 3’; Trp53 5’ GGTTAAACCCAGCTTGACCA
3’ and 5’ GGAGGCAGAGACAGTTGGAG 3’). Experimental animals resulted from crosses between
Kdm6aFlox/+ and Trp53Flox/+ mice.
Adenovirus infection of organoids
To generate Trp53-/-, Kdm6a-, and Trp53-/-;Kdm6a- organoids, Trp53Flox/Flox, Kdm6aFlox, and
Trp53Flox/Flox;Kdm6aFlox organoids were infected with Ad5CMVCre-eGFP adenovirus (University of
Iowa Viral Vector Core) in vitro. Organoids were trypsinized into single cells. 500,000 cells were pel-
leted in a 1.5-mL tube and re-suspended in 100 mL of organoid medium supplemented with a final
concentration of 5 mg/mL polybrene (TR-1003-G Millipore) with or without virus at a MOI of 50. Cells
were incubated at 32˚C with shaking at 700 rpm on an Eppendorf ThermoMixer for 1 hr. Cells were
then incubated at 37˚C without shaking for approximately 2.5 hr. Cells were pelleted and re-sus-
pended in 650 mL Matrigel to make twelve 50 mL Matrigel tabs. Tabs were hardened at 37˚C for 15
min and organoid medium was added. To verify recombination of floxed alleles, DNA was isolated
from organoid cell pellets using the DNeasy Blood and Tissue Kit (69506 Qiagen, Germany) and gen-
otyped via PCR using the primers listed in Key Resources.
Expression vector construction
Wild-type human RXRA was expressed from pBABE puro RXRA (plasmid #11441 Addgene). Point
mutations were introduced via the QuikChange Site-Directed Mutagenesis protocol (Agilent
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Technologies). pBABE puro empty vector was generated by digesting pBABE puro RXRA with EcoRI
to remove RXRA and by ligating the plasmid ends together with T4 DNA ligase (M0202S New Eng-
land BioLabs). Wild-type human PPARG1 was expressed from pCMV6-XL4 PPARG (SC108192 Ori-
gene). Point mutations were introduced via the QuikChange Site-Directed Mutagenesis protocol.
pCMV6-XL4 empty vector was generated by digesting pCMV6-XL4 PPARG with NotI to remove
PPARG and by ligating the plasmid ends together with T4 DNA ligase. Human PPARD was cloned
from JMSU-1 epithelial bladder cancer cells. Cells were harvested upon reaching 80–90% confluency
and total RNA was isolated using the RNeasy Mini Kit. JMSU-1 cDNA was generated using a First-
Strand cDNA Synthesis Kit (27-9261-01 GE Healthcare Life Sciences) with random hexameric primers
and 5 mg total RNA. Primers targeting the 5’ and 3’ UTRs were used to amplify PPARD. PPARD was
inserted into the pCMV6-XL4 expression vector using the In-Fusion HD Cloning System (639646
Clontech). Point mutations were introduced via the QuikChange Site-Directed Mutagenesis protocol.
See Key Resources for primer sequences.
Cell lines
JMSU-1, 575A, and UM-UC-3 were obtained from Dr. David Solit (MSKCC). 293 Lenti-X cells were
obtained from Clonetech. Cells were cultured in recommended medium supplemented with 10%
fetal bovine serum (FBS; FB-11 Omega Scientific), 1% penicillin-streptomycin (15140122 Gibco), and
1x GlutaMAX Supplement (35050061 Gibco). Cells were grown at 37˚C in 5% CO2.
Retroviral infections
Retrovirus was produced by using LipoD293 DNA In Vitro Transfection Reagent (SL100668 SignaGen
Laboratories) to transiently transfect 293 Lenti-X cells with 0.45 mg VSVG, 2.27 mg pCL-ampho, and
2.27 mg pBABE puro empty vector, RXRA WT, RXRA S427F, or RXRA S427Y in a 100 mm TC-treated
tissue culture dish. Medium was replaced with recommended culturing medium approximately 6 hr
post-transfection. Retrovirus was collected 48 hr post-transfection and was filtered through a 0.45-m
M filter. Stable cells lines were generated by seeding cells in a 100 mm TC-treated tissue culture
dish 18–24 hr before adding virus so that cell confluency was 50–70% when virus was added. The
next day, medium was removed and retrovirus diluted 1:4 in the recommended culturing medium
and supplemented with a final concentration of 8 mg/mL polybrene (TR-1003-G Millipore) was added
to the cells. After approximately 24 hr, the virus-containing medium was replaced with fresh
medium. Cells were cultured for an additional 36 hr, at which time puromycin (P8833 Sigma-Aldrich)
was added at a predetermined concentration to select for transduced cells. To generate stable orga-
noid lines, organoids were trypsinized into single cells. 500,000 cells were pelleted in a 1.5-mL tube
and resuspended in 500 mL of 1:1 organoid medium:retrovirus mixture supplemented with a final
concentration of 8 mg/mL polybrene. Cells were incubated at 32˚C with shaking at 600 rpm on an
Eppendorf ThermoMixer for 1.5 hr. Cells were then incubated at 37˚C without shaking for approxi-
mately 5 hr. Cells were pelleted and resuspended in enough Matrigel to make three 50 mL Matrigel
tabs. Tabs were hardened at 37˚C for 15 min and organoid medium was added. 48 hr after infection,
puromycin was added at a predetermined concentration to select for transduced cells.
siRNA knockdown
Cells were seeded in a 12-well cell culture plate 18–24 hr before transfection so that cell confluency
was 50–70% at time of transfection. PepMute siRNA Transfection Reagent (SL100566 SignaGen Lab-
oratories) was used to transiently transfect cells with ON-TARGETplus Non-targeting Pool (D-
001810-10-20 Dharmacon), ON-TARGETplus Human PPARG siRNA (L-003436-00-0005 Dharmacon),
and/or ON-TARGETplus Human PPARD siRNA (L-003435-00-0005 Dharmacon). PepMute/siRNA
complex-containing medium was replaced with recommended culturing medium approximately 24
hr post transfection. Cells were collected 72 hr post transfection.
Western blotting
Cells and organoids were lysed in M-PER (78501 Thermo Scientific) supplemented with 1x Halt Pro-
tease Inhibitor Cocktail (87786 ThermoFisher Scientific) and 0.45 M NaCl for 10 min on ice with peri-
odic vortexing. Lysates were cleared by centrifugation at 18,000 x g for 15 min. Protein
concentration was determined with Pierce BCA Protein Assay (23224/23228 ThermoFisher Scientific).
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Protein lysates were denatured by boiling in 1x Bolt LDS Sample Buffer (B0008 Invitrogen) and 1x
NuPAGE Sample Reducing Reagent (NP0004 Invitrogen) for 10 min. Proteins were separated on
Bolt 4–12% Bis-Tris Plus Gels (NW04122BOX Invitrogen), transferred onto Immobilon-P Membrane,
PVDF, 0.45 mM (IPVH00010 Millipore), and blocked according to antibody specifications. Blots were
incubated with primary antibody in blocking solution overnight at 4˚C. Blots were washed with 1x
TBS plus 0.1% Tween and primary antibodies were detected with HRP-conjugated secondary anti-
bodies. Amersham ECL Prime western blotting detection reagent (RPN2232 GE Healthcare Life Sci-
ences) or Clarity Western ECL Substrate (170–5060 Bio-Rad) was used for chemiluminescence and
luminescence was detected with the Bio-Rad ChemiDoc XRS + System. Antibodies and concentra-
tion list in Key Resources
RNA isolation, cDNA synthesis, and RT-qPCR
RNeasy Mini Kit (74106 Qiagen) was used to isolate RNA from organoid and cell pellets. iScript
cDNA Synthesis Kit (1708891 Bio-Rad) was used to synthesize cDNA from 0.5 to 1 mg of RNA. RT-
qPCR was performed according to package instructions for SsoFast EvaGreen Supermix with low
ROX (172–5211 Bio-Rad) on the Applied Biosystems QuantStudio 3 Real-Time PCR system. See Key
Resources for primer sequences used.
Reporter assays
Cells were seeded in a 48-well cell culture plate 18–24 hr before transfection so that cell density was
approximately 70% at time of transfection. LipoD293 DNA In Vitro Transfection Reagent (SL100668
SignaGen Laboratories) was used to transiently transfect cells with a reporter plasmid, expression
vectors, and a plasmid expressing Renilla luciferase. LipoD293/DNA complex-containing medium
was replaced with recommended culturing medium supplemented with 1% FBS 16–18 hr post-trans-
fection. Drugs were added to cells 48 hr post transfection. Drug-containing medium was removed
16 hr later and cells were washed with 1x PBS. Luciferase activity was assayed using Dual-Glo Lucifer-
ase Assay System (E2940 Promega) and in accordance with the Dual-Glo protocol except that a 1:1
mixture of 1xPBS:Dual-Glo Reagent was added to the cells. Luminescence was measured on the
SpectraMax i3 Platform (Molecular Devices). See Key Resources for list of plasmids.
Growth assays
Organoids were plated at 1000 or 1500 cells per tab and cultured in normal or EGF deplete orga-
noid medium, respectively, for 8–10 days. Drugs or DMSO were added to medium at time of plat-
ing. Medium was changed every 4 days post-plating. Cell viability was measured day 1 (baseline
measurement) and at indicated days post-plating using CellTiter-Glo (G7571 Promega). Briefly, tabs
were homogenized in 1:1 mixture of 1xPBS:CellTiter-Glo reagent and incubated at room tempera-
ture for 10 min with shaking. Homogenate was transferred to a white, 96-well plate and lumines-
cence was measured on the SpectraMax i3 Platform. For organoid counting assay, organoids were
digested into a single-cell suspension with trypsin and the counted in duplicate using a Bio-rad
TC20.
RNA-seq sample preparation
Cells were seeded in biological triplicate in 6-well tissue culture plates at 300,000 cells (JMSU-1) or
125,000 (575A) cells per well. 48 hr later, 0.1% DMSO or 1 mM pioglitazone (E6910 Sigma-Aldrich)
was added to cells. RNA was isolated with the RNeasy Mini Kit (74106 Qiagen) 16–18 hr after addi-
tion of drugs. RNA library prep and sequencing were done by the Genome Technology Access Cen-
ter in the Department of Genetics at Washington University School of Medicine. Briefly, Ribosomal
RNA was removed by poly-A selection using Oligo-dT beads. mRNA was then fragmented and
reverse transcribed to yield double stranded cDNA using random hexamers. cDNA was blunt ended,
had an A base added to the 3’ ends, and then had Illumina sequencing adapters ligated to the ends.
Ligated fragments were then amplified for 12 cycles using primers incorporating unique index tags.
Fragments were sequenced on an Illumina HiSeq-2500 or HiSeq-3000 using single reads extending
50 bases.
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RNA-seq data acquisition, quality control, and processing
RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version
2.0.4b. Gene counts were derived from the number of uniquely aligned unambiguous reads by Sub-
read:featureCount version 1.4.5. Transcript counts were produced by Sailfish version 0.6.3. Sequenc-
ing performance was assessed for total number of aligned reads, total number of uniquely aligned
reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distri-
bution over known gene models with RSeQC version 2.3. All gene-level and transcript counts were
then imported into the R/Bioconductor package EdgeR and TMM normalization size factors were
calculated to adjust for samples for differences in library size. Genes or transcripts not expressed in
any sample were excluded from further analysis. The TMM size factors and the matrix of counts were
then imported into R/Bioconductor package Limma and weighted likelihoods based on the observed
mean-variance relationship of every gene/transcript and sample were then calculated for all samples
with the voomWithQualityWeights function. Performance of the samples was assessed with a spear-
man correlation matrix and multidimensional scaling plots. Gene/transcript performance was
assessed with plots of residual standard deviation of every gene to their average log-count with a
robustly fitted trend line of the residuals. Generalized linear models were then created to test for
gene/transcript level differential expression. Differentially expressed genes and transcripts were
then filtered for FDR adjusted p-values less than or equal to 0.05. Go-Elite version 1.2 was used to
identify over-represented pathways curated by KEGG.
ChIP-seq sample preparation
JMSU-1 cells stably expressing RXRAwt or RXRAS427F were seeded in biological triplicate in 150 mm
TC-treated culture dish and collected when 70–90% confluency was reached. Crosslinking and ChIP
were performed as described for adherent cells in the ENCODE experiment summary for
ENCSR000BJW (https://www.encodeproject.org/experiments/ENCSR000BJW/). Chromatin was son-
icated using the Diagenode Pico Bioruptor. DNA-protein complexes were precipitated with antibod-
ies against RXRA (PP-K8508-00 R and D Systems) and H3K27Ac (ab4729 Abcam). Ovation Ultralow
System V2 (0344–32 NuGen) was used to generate the sequencing library. The library was
sequenced by the Genome Technology Access Center in the Department of Genetics at Washington
University School of Medicine.
ChIP-seq data analysis
Reads were aligned to hg19 using NovoAlign version 3.04.06 with the command novoalign -r None
-l 30 -e 100 -i 230 140 –H. For the RXRA and H3K27ac IPs, peaks were called for each phenotype
using the IDR (Li et al., 2011) pipeline described here (Kundaje, 2012) with MACS version 2.1.1
(Zhang et al., 2008) as the peak caller. RAE regions were defined for each phenotype by running
bedtools intersect on the H3K27ac and RXRA IDR peak lists. Differential binding analysis was per-
formed on the H3K27ac signal using DiffBind (Ross-Innes et al., 2012) comparing mutant to wild-
type with the IDR peak lists as input and an FDR cutoff of 0.05. Motif analysis of the RAE regions
was performed using HOMER version 4.9 (Heinz et al., 2010) with the command findMotifsGe-
nome.pl –h –bg <Background> <Peaklist> hg19. Peaklist was the RAE regions found by DiffBind to
have higher H3K27ac binding in mutant. Background was the list of all RAE regions minus the ones
found in peaklist.
Preparation of structures for molecular dynamics simulations
The published structure of complexed RXRA/PPARG LBDs bound to agonist (PDB: 1FM6)
(Gampe et al., 2000) was used as the starting conformation for simulations. To reduce subsequent
computational complexity and enable drift towards an inactive state during simulations, the respec-
tive agonist structures binding RXRA and PPARG were removed. The small peads were aligned to
hg19 usptide nuclear receptor coactivator 1 (NCOA1) bound to both RXRA and PPARG AF2
domains was also removed with the same purpose. The Chimera molecular visualization tool
(Pettersen et al., 2004) was used to mutate RXRA serine 427 to phenylalanine (RXRA S427F), creat-
ing wild-type and mutant structures for subsequent simulations.
Halstead et al. eLife 2017;6:e30862. DOI: https://doi.org/10.7554/eLife.30862 22 of 27
Research article Cancer Biology
Molecular dynamics simulations
The protocol described by Hart et. al. was used for molecular dynamics simulations (Hart et al.,
2016). Briefly, simulations were performed using the molecular dynamics package GROMACS 5.1.3
(Abraham et al., 2015). The Amber03 force field (Duan et al., 2003) was used and hydrogen atoms
in each structure were replaced with virtual sites. The protein structure was solvated within a
dodecahedron whose border was at least 10 A˚ away from the protein in all directions. Chlorine
counterions were added to neutralize the system’s overall positive charge. To ensure the system
contains no steric clashes or inappropriate geometry, energy minimization was used to relax the sys-
tem below a 1000 kJ/mol/nm threshold. To equilibrate solvent and ions around the structure, the
system underwent position-restrained molecular dynamics simulation for one nanosecond using a
step size of 4 fs. After relaxation and equilibration, each system was subjected to long-timescale
molecular simulations. Simulations took place using the NPT ensemble at 1 bar and 300 K. Parri-
nello-Rahman pressure coupling (Parrinello and Rahman, 1981) and the V-rescale thermostat
(Bussi et al., 2007) were used during simulations. The LINCS method (Hess, 2008) constrained
hydrogen bonds and allowed the use of virtual sites. The cutoffs for electrostatic and van der Waals
interactions was 9 A˚. Periodic boundary conditions were applied during simulation and the particle-
mesh Ewald summation reconstituted any long-distance electrostatic interactions. Each simulation
lasted 100 nanoseconds with conformations stored every 10 picoseconds. Ten simulations were run
to produce an aggregate 1 microsecond of simulation for both wild-type and mutant conditions.
Markov state modeling
MSMBuilder 2.8 (Beauchamp et al., 2011) was used to analyze conformations adopted during
molecular simulation. Wild-type and mutant structures were clustered in overlapping state space
using the hybrid k-centers/k-medoids technique. Clustering was based on the RMSD of between
backbone-heavy atoms from PPARG 445–477 and RXRA 425–429. The inter-cluster distance cutoff
was 1 A˚ and 50 iterations were performed to refine cluster assignment. A microstate Markov state
model (MSM) was constructed using the Transpose method for symmetric counts matrix estimation
and without applying an ergodic trim. The 5% most frequently occupied microstates during wild-
type and mutant conformations were selected. Distance between alpha carbons of RXRA 427 and
PPARG 477 was calculated for comparison between microstate structures from wild-type and mutant
simulations. The inter-residue distances were normalized to the respective distance in the agonist-
bound crystal structure. The Chimera molecular visualization tool was used to generate representa-
tive figures.
Statistics
All statistical tests are as indicated in figure legends. Analysis was done in GraphPad Prism with the
exception of pearson coefficients which were calculated using Microsoft Excel. All statistical compar-
isons are two-tailed. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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